infliximab

Home
Ligands
infliximab

GtoPdb Ligand ID: 5004

infliximab is an approved drug (FDA (1998), EMA (1999))

Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications	References
infliximab-dyyb; CT-P13	Remsima; Inflectra; Flammegis	Celltrion/Pfizer	Approved (2013 EMA, 2016 FDA)	As per reference agent	[1-2,8]
infliximab-abda; SB2	Flixabi; Renflexis	Merck/SamsungBioepis	Approved (2016 EMA, 2017 FDA)	As per reference agent
infliximab-qbtx; PF-06438179	Ixifi; Zessly	Pfizer?Sandoz	Approved (2017 FDA, 2018 EMA)	As per reference agent	[3]
NI-071		Nichi-Iko Pharmaceutical	Approved (2017 Japan); Phase 3 US (NCT02990806)	As per reference agent
BCD-055		Biocad	Ph 3 (NCT02762838)	Rheumatoid arthritis
Infliximab-EPIRUS; BOW015	Infimab	Epirus Biopharmaceuticals	Approved (2014 India); Ph 3 US (NCT02683564)	Rheumatoid arthritis
infliximab-axxq; ABP710	Avsola	Amgen	Approved (2019 FDA)	As per reference agent
STI-002		MabTech/Sorrento Therapeutic
Infliximab biosimilar 1		Nippon Kayaku	Approved (Japan 2014)	As per reference agent

Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].

View more information in the IUPHAR Pharmacology Education Project: infliximab

References
1. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]
2. Blair HA, Deeks ED. (2016) Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. BioDrugs, 30 (5): 469-480. [PMID:27650650]
3. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016) Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab). Adv Ther, 33 (11): 1964-1982. [PMID:27585978]
4. Generics and Biosimilars Initiative. Biosimilars approved in Japan. Accessed on 25/01/2019. Modified on 25/01/2019. gabionline.net, http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan
5. Le J, Vilcek J, Dadonna P, Ghrayeb J, Knight D, Siegel SA. (1997) Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies. Patent number: US5656272. Assignee: New York University Medical Center, Centocor, Inc.. Priority date: 18/03/1991. Publication date: 12/08/1997.
6. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 117 (4): 761-9. [PMID:10500056]
7. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology, 109 (1): 129-35. [PMID:7797011]
8. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis, 76 (2): 355-363. [PMID:27130908]

References

1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]

2. Blair HA, Deeks ED. (2016)
Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
BioDrugs, 30 (5): 469-480. [PMID:27650650]

3. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016)
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).
Adv Ther, 33 (11): 1964-1982. [PMID:27585978]

4. Generics and Biosimilars Initiative.
Biosimilars approved in Japan.
Accessed on 25/01/2019. Modified on 25/01/2019. gabionline.net, http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan

5. Le J, Vilcek J, Dadonna P, Ghrayeb J, Knight D, Siegel SA. (1997)
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies.
Patent number: US5656272. Assignee: New York University Medical Center, Centocor, Inc.. Priority date: 18/03/1991. Publication date: 12/08/1997.

6. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology, 117 (4): 761-9. [PMID:10500056]

7. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995)
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology, 109 (1): 129-35. [PMID:7797011]

8. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Ann Rheum Dis, 76 (2): 355-363. [PMID:27130908]